In a recent randomized, placebo-controlled trial, consolidation treatment with brentuximab vedotin (BV) decreased the risk of Hodgkin lymphoma (HL) progression after autologous stem cell transplantation (ASCT). However, the impact of BV consolidation on overall survival, quality of life, and health care costs remain unclear. METHODS: A Markov decision-analytic model was constructed to measure the costs and clinical outcomes for BV consolidation therapy compared with active surveillance in a cohort of patients aged 33 years who were at risk for HL relapse after ASCT. Life-time costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs) were calculated for each post-ASCT strategy. RESULTS: After quality-of-life adjustments and standard discounting, upfront BV consolidation was associated with an improvement of 1.07 QALYs compared with active surveillance plus BV as salvage. However, the strategy of BV consolidation led to significantly higher health care costs ($378,832 vs $219,761), resulting in an ICER for BV consolidation compared with active surveillance of $148,664/QALY. If indication-specific pricing was implemented, then the model-estimated BV price reductions of 18% to 38% for the consolidative setting would translate into ICERs of $100,000 and $50,000 per QALY, respectively. These findings were consistent on 1-way and probabilistic sensitivity analyses. CONCLUSIONS: BV as consolidation therapy under current US pricing is unlikely to be cost effective at a willingness-to-pay threshold of $100,000 per QALY. However, indication-specific price reductions for the consolidative setting could reduce ICERs to widely acceptable values. Cancer 2017;123:3763-71. V C 2017 American Cancer Society.
INTRODUCTION
Although the majority of individuals with Hodgkin lymphoma (HL) experience durable remissions after modern first-line chemotherapy, greater than 20% to 30% of patients are refractory to initial treatment or experience disease relapse after initial remission. [1] [2] [3] [4] For patients with relapsed or primary refractory HL, the standard of care is high-dose chemotherapy followed by autologous stem cell transplantation (ASCT). Despite this intensive treatment, approximately 50% will relapse and die from HL after ASCT. [5] [6] [7] [8] [9] [10] Primary refractory disease, progression within 12 months of an initial response to frontline therapy, and extranodal involvement before salvage therapy portend the greatest risk of post-ASCT relapse. 8, 11, 12 For these individuals at greatest risk for HL progression, additional therapeutic strategies after transplantation may offer clinical benefit.
The antitumor necrosis factor superfamily member 8 (cluster of differentiation 30 [anti-CD30], a cell membrane protein) antibody drug conjugate brentuximab vedotin (BV) first demonstrated high efficacy in individuals with relapsed HL after ASCT or in those who were not deemed candidates for intensive therapy. 13, 14 More recently, the double-blind, placebo-controlled, phase 3 AETHERA trial evaluated BV as early consolidation after ASCT in individuals who had HL and unfavorable risk factors. 15 The study demonstrated a significant improvement in progression-free survival (PFS) for the BV-treated group compared with the placebo group (42.9 vs 24.1 months). 15 At a median observation time of 30 months, no significant difference in overall survival was detected. However, the PFS improvement led the US Food and Drug Administration to add post-ASCT consolidation to the BV label and converted the accelerated approval status of BV to traditional approval. 16 Adding pre-emptive BV to the post-ASCT setting comes at a time of increased scrutiny on drug prices, with many calling for interventions to better align drug prices with clinical utility. [17] [18] [19] Fortunately, robust clinical trial and quality-of-life data were captured when testing BV consolidation, affording the opportunity to appraise consolidative BV using value-based assessment. In the current study, we use a Markov decision-analytic model to compare the cost-effectiveness of BV as consolidation therapy versus active surveillance with BV as salvage after ASCT.
MATERIALS AND METHODS

Patients and Intervention
Our baseline sample was constructed to mirror the population enrolled in the AETHERA trial. 15 The age of our patient cohort was 33 years, and all individuals had at least 1 risk factor for progression after ASCT: primary refractory HL, relapsed HL with an initial remission duration <12 months, or extranodal involvement at the start of pretransplantation salvage chemotherapy. Similar to the clinical trial, individuals entered our model after ASCT and received either consolidation with BV (1.8 mg/kg every 3 weeks for a maximum of 16 cycles) or active surveillance with BV at the time of HL progression (placebo arm). 15 
Model Construction
We developed a Markov decision-analytic model to compare the costs and clinical outcomes associated with post-ASCT BV consolidation versus active surveillance. In the baseline model (Fig. 1) , individuals enter the model after ASCT and receive either BV consolidation or active surveillance. Four additional health-transition states are used to capture the post-ASCT period until death: HL relapse treated with BV, HL relapse post-BV treatment, long-term durable second remission, and death. Individuals who relapsed on active surveillance first received salvage with BV. Patients who had HL progression after BV consolidation or BV salvage entered the relapse post-BV health state, in which they received salvage chemotherapy, immunotherapy (nivolumab), and/or allogeneic stem cell transplantation.
We used 3-month transition-state cycles and a lifetime horizon to estimate direct health care costs and utilities experienced as individuals transitioned from ASCT until death. Costs and utilities were assigned to each health state, and transition probabilities were derived from published studies. Cost-benefit analysis was conducted from a societal perspective within the United States, and all future costs and benefits were discounted at a standard rate of 3% annually. 20 The primary outputs of the model were used to calculate the incremental cost in US dollars for an additional QALY gained comparing BV consolidation versus active surveillance (the incremental cost-effectiveness ratio [ICER] ). We assumed a willingness-to-pay threshold of $100,000 per QALY gained. The resulting model was constructed using TreeAge Pro software (TreeAge Software, Williamstown, MA). Additional statistical analyses were performed using STATA 13 (StataCorp, College Station, TX) and R version 3.2.5 (R Core Team, Austria, Vienna; www.R-project.org) Accessed May 12, 2017.
Transition Probabilities
Base-case estimates and ranges for health-state transition probabilities are listed in Table 1 . 15, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] When available, results from randomized controlled trials were used to inform clinical probabilities. We estimated rates of HL progression after ASCT out to 5 years using standard extrapolation methods. 15, [21] [22] [23] Here, we first reconstructed individual patient-level PFS data from the AETHERA Kaplan-Meier curves and at-risk tables, which were published at a median observation time of 30 months. 15 Individual-level data were then fit with standard parametric models (Gompertz, exponential, log-logistic, Weilbull). 21, 22, 34, 35 Both the BV consolidation and placebo arms were best fit with Gompertz functions, and the predicted 5-year PFS rate was 54% for BV consolidation compared with 43% for placebo (Supporting Fig. 1 ; see online supporting information). All patients in our model remained at risk for HL progression up to 5 years post-ASCT. After 5 years, individuals experienced age-adjusted mortality from other causes based on US Life Tables. Finally, we incorporated several recently published studies to derive transition probabilities after HL relapse. These included recently published long-term follow-up data for BV monotherapy in the salvage setting and separate reports supporting the use of nivolumab after BV failure. 24, 29, 30 Costs Baseline direct medical costs were derived from the 2016 Medicare fee schedule and the medical literature (Table 2) . [36] [37] [38] [39] [40] [41] Costs were converted into 2016 US dollars using the Medical Care component of the Consumer Price Index. Consistent with the Medicare pricing policy, we used 106% of the manufacturer's 2016 average sales price for drug costs. 17, 42 Our drug cost calculations assume that patients weighed 70 kg, but account for drug wastage by rounding up to the next full single-use vial size available for each dose administered. 43, 44 For example, BV is only available in 50-mg, single-use vials. Therefore, 3 vials per dose were used for our 70-kg patients (1.8 mg/ kg per dose), and BV costs were based on the full 150 mg charged per dose. Costs for allogeneic transplantation and traditional salvage chemotherapy were based on values 15 Diaby 2014, 21 Latimer 2013, 22 Guyot 2012 15 Diaby 2014, 21 Latimer 2013, 22 Guyot 2012 23 Probability of remission after BV salvage 0.09 0.05-0. 13 Younes 2010, 13 Gopal 2015, 24 Chen 2016 25 No. of BV doses in salvage setting 10 8-12
Younes 2010 13 Probability of receiving allo-SCT 0.3 0.26-0. 35 Younes 2010, 13 Chen 2016, 25 Chen 2014, 26 Anderlini 2016, 27 Moskowitz 2009 used in previous studies. [38] [39] [40] The cost of monitoring included office visits and routine laboratory tests. Endof-life health care costs were estimated from published data on the cost of care in the last year of life for patients with cancer compared with the general Medicare population.
36,37
Utilities
Baseline clinical utilities for various health states were based on values used in previous studies and the published literature (Table 3) . 40, 45, 46 In particular, results from the AETHERA trial's companion quality-of-life study informed our clinical utilities in the post-ASCT setting. 45 Individuals enrolled in AETHERA completed the EuroQol Five-Dimensions Questionnaire (EQ-5D) every 3 months for the first 2 years on study, and the published results displayed scores by treatment arm (BV consolidation vs placebo) and disease status (ongoing remission vs progressive disease). 45 We used digitizer software to directly capture the mean EQ-5D score reported by participants in the AETHERA trial (GetData Graph Digitizer version 2.24; http://www.getdata-graph-digitizer.com Accessed May 12, 2017). 45 EQ-5D scores at 3-month intervals by treatment arm informed our model utilities through the first 2 years, and pooled mean scores at 2 years were used for our long-term remission (pooled mean score, 0.89) and progression (pooled mean score, 0.67) states. Furthermore, we considered a range of clinical utilities based on prior literature during sensitivity analysis. 46 
Sensitivity Analysis
We performed a series of sensitivity analyses to account for uncertainty and to evaluate the robustness of our model conclusions. In 1-way sensitivity analyses, we varied the value of our model parameters 1 at a time to examine the effects on the ICER. During probabilistic sensitivity analysis, we performed 10,000 Monte Carlo simulations, each time randomly sampling from the distributions of model inputs. Clinical probabilities and health utilities were represented by b distributions, whereas costs were represented by c distributions. Patient age also varied during probabilistic sensitivity analysis and mirrored participant age in the AETHERA trial. 15 
RESULTS
Baseline Analysis
Results of the baseline cost-effectiveness analysis are summarized in 40 Ramsey 2015, 45 Swinburn 2015 46 Abbreviations: BV, brentuximab vedotin; QALY, quality-adjusted life-years. Abbreviations: BV, brentuximab vedotin; CI, confidence interval; ICER, incremental cost-effectiveness ratio; PSA, probabilistic sensitivity analyses; QALY, quality-adjusted life-year.
consolidation therapy was associated with an improvement of 1.07 QALYs compared with active surveillance. Therefore, the ICER for BV consolidation compared with active surveillance was estimated at $148,664 per QALY.
Sensitivity Analyses
The results of 1-way sensitivity analyses are presented in Figure 2 . Model parameters with the greatest influence on the ICER were discount rate, probability of remission after BV rescue, and starting age of the patient cohort. For example, varying the probability of long-term durable remission after salvage BV between 5% and 12.7% caused the ICER to increase from $107,540 to $231,904. Less pronounced ICER changes were observed when we varied nondrug costs and clinical utilities. Across broad ranges for each parameter, all ICERs in our 1-way sensitivity analyses remained greater than $100,000 per QALY. In addition to standard 1-way sensitivity analysis, we considered a scenario in which indication-specific pricing was implemented. Here, BV used in the salvage setting remained at current pricing (approximately $6464 per 50-mg vial), but BV for consolidation was discounted. Our model estimates that price reductions from 18% to 38% for BV in the consolidative setting would translate into ICERs of $100,000 per QALY and $50,000 per QALY, respectively (Supporting Fig. 2 ; see online supporting information).
A summary of probabilistic sensitivity analysis is provided in Table 4 . No iteration during our 10,000 sample simulation had an ICER below a threshold of $50,000 per QALY; and only 3% of iterations had an ICER below $100,000. In total, 95% of iterations during our Monte Carlo simulation produced ICERs for BV compared with active surveillance between $97,134 and $282,171 per QALY.
DISCUSSION
Although first-line chemotherapy is highly effective for the majority of individuals with HL, outcomes in those with refractory or relapsed HL is poor. [5] [6] [7] [8] [9] [10] 47 BV, as an anti-CD30 antibody-drug conjugate, has clear efficacy as a single-agent in the relapsed HL setting, including the potential for long-term durable remissions in a small subset of individuals. 13, 14 With efficacy clearly established in relapsed and refractory HL, investigations testing BV in the first-line setting are underway. 48, 49 In addition, the recently published AETHERA trial measured the efficacy of pre-emptive use of BV as consolidation therapy 4 to 6 weeks after ASCT for patients at high risk of HL relapse. 15 In that trial, consolidation with BV was associated with significant improvements in PFS compared with placebo. 15 Although consolidation with BV offers improvement in PFS, its impact on survival, quality of life, and health care costs was uncertain. Our analysis incorporated data from the AETHERA trial alongside clinical utilities and health care costs to calculate the cost effectiveness of pre-emptive BV consolidation versus active surveillance with BV as salvage. The incremental clinical benefit of BV consolidation was associated with significant health care expenditures, producing an ICER of $148,664 per QALY. ICERs remained greater than $100,000 per QALY in 1-way sensitivity analyses, and the conclusions were robust during probabilistic sensitivity analysis.
Decision-analytic models are subject to inherent limitations related to the data available to populate the model; however, our study has several notable strengths. First, our model was based on results from a large, randomized, placebo-controlled, double-blinded trial directly comparing BV consolidation versus placebo (which was active surveillance in our model). 15 Second, clinical utility estimates for BV consolidation and post-ASCT surveillance were available from the AETHERA companion study, which measured quality of life during the clinical trial. 15, 45 Our model also incorporated contemporary data to reflect recent advances in the treatment and outcomes of individuals with refractory or relapsed HL after ASCT. 24, 29, 30 Finally, cost-effectiveness analyses evaluating new drugs for hematologic malignancies infrequently consider drug wastage in cost calculations. 31 Because the economic impact of drug wastage can be substantial, 42 we chose to calculate costs for novel drugs based on the number of single-use vials used rather than the actual dose administered.
Although our study has several strengths, limitations exist. First, our model accounts for treatment discontinuation because of toxicity, but it does not address dose reductions that can occur during treatment with BV. 13, 15 Peripheral neuropathy is the most frequent cause of BV dose reduction and is more likely to occur in later cycles related to cumulative drug exposure. 50 Because we calculated drug costs by the number of vials used per dose, our model is less sensitive to minor dose modifications. However, even when we performed a sensitivity analysis reducing the number of vials used in 20% of all BV administrations to 2 vials instead of 3, the ICER for BV consolidation remained greater than $100,000 per QALY (data not shown).
Second, despite having randomized clinical trial information for much of our Markov model, uncertainly currently exists concerning post-ASCT relapse because of recent clinical advancements with relatively short-term follow-up. 29, 30 In our model, patients who relapsed after BV (BV consolidation or BV salvage) received the same HL-directed treatment. In these heavily pretreated patients, our model included the use of salvage chemotherapy, programmed death 1 (PD-1) blockade by nivolumab, and/or allogeneic stem cell transplantation. 1 We grouped these treatments into a single health state by using published clinical data on therapy for patients with HL who relapse after receiving both ASCT and BV. The probability of undergoing allogeneic transplantation and the likelihood of a durable remission after transplantation were extracted from available observational studies. 13, [25] [26] [27] [28] Likewise, the estimated cost of salvage therapy beyond BV was summed from the estimated percentage of heavily pretreated patients who receive salvage chemotherapy, nivolumab, and/or allogeneic transplantation and the respective costs of the 3 treatment modalities. When available, we incorporated published literature to estimate the cost and utilities of relapse beyond BV and performed extensive sensitivity analyses. For example, we varied the number of nivolumab cycles from 12 to 37 based on the published report of nivolumab for HL after BV failure. 29 Despite considering a wide range of nivolumab cycles during sensitivity analyses, calculated ICERs remained stable between $143,168 and $149,229 per QALY. Even when we performed a sensitivity analysis attributing a cost of $1,000,000 per QALY gained during the post-BV relapse state, our ICER for BV consolidation remained greater than $100,000 per QALY.
Because our model is most influenced by parameters that inform health transition states before the development of BV-refractory disease, our model conclusions are robust despite the uncertainties surrounding recent treatment advances for HL beyond ASCT and BV. However, it remains possible that consolidation with BV would be cost effective for a subgroup of patients at very high risk for relapse, for whom consolidation with BV appeared to offer particular benefit. 51 Furthermore, our AETHERAderived model applies to individuals who received chemotherapy in the pretransplantation setting and may not translate into future HL settings in which brentuximab and/or immunotherapy are used in earlier lines of therapy. Finally, our cost-effectiveness analysis considers only direct health care expenditures, and future economic benefits related to improved survival in our relatively young patient population could be considerable.
Original Article
Overall, our current study suggests that the use of BV as consolidation therapy at current US pricing is unlikely to be cost effective at a willingness-to-pay threshold of $100,000 per QALY. Although there continues to be deliberation about defining acceptable costeffectiveness thresholds, 52 recent data suggest that rising costs of new anticancer drugs are only modestly associated with clinical benefits. 53 With the cost of cancer treatments increasing 10-fold since 2000, 54, 55 our finding of an unfavorable ICER is not unique among anticancer therapies. 56, 57 Indeed, a recently published systematic review indicated that many treatments for hematologic cancers that previously were considered to have acceptable ICERs were no longer cost effective when considering presentday US drug prices. 58 Cancer treatment prices are increasingly recognized as unsustainable, and several potential solutions are under consideration. 18, 19 Whereas cost-effectiveness analyses can inform value-based pricing, the quality of such analyses depends on the availability of robust comparative data. Our cost-effectiveness analysis used data from a randomized, double-blinded clinical trial that included a clinically relevant control arm and a companion quality-of-life study. Unfortunately, this level of data is all too uncommon in today's clinical trial environment, because industrysponsored trials frequently use control arms that do not represent current treatment standards. 59, 60 This makes direct comparisons difficult in many oncology settings and increases uncertainty for cost-effectiveness analyses.
In the setting of HL after ASCT, approximately 50% of individuals will remain free from HL recurrence without additional therapy. [5] [6] [7] [8] [9] [10] Even when selecting patients at high risk using clinical parameters, 15 considerable proportions remain in remission post-ASCT and are unlikely to benefit from upfront consolidation with BV. Among patients with confirmed HL relapse post-ASCT, an overwhelming majority will derive clinical benefit from BV therapy. Under indication-specific pricing, BV in the consolidation setting would be priced lower than BV used for post-ASCT salvage; ultimately, our model indicated that price reductions for BV in the consolidative setting from 18% to 38% produced more reasonable ICERs of $100,000 per QALY and $50,000 per QALY, respectively.
Value-based and indication-specific pricing has the potential to align drug prices with their underlying clinical utility and continue to reward highly effective cancer therapy. Although it is currently an academic exercise, future cost-effectiveness analysis similar to ours could assist with transparent and more equitable drug pricing in the United States and abroad. This will only be possible with broad buy-in from health care stakeholders and a renewed focus on conducting clinical trials with relevant control arms and robust, real-world comparative-effectiveness research.
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